A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide
Only 2/41 studies (≈5%) reported or assessed dietary intake or evaluated diet changes secondary to GLP-1/GIP RA medication use. This review highlights a major gap in the evidence requiring urgent attention. More high-quality research, using validated dietary assessment methods as outcome measures in RCTs is needed to understand how these medications impact diet and diet quality, nutrient intake, and chronic disease risk.
Authors
- Paulina Nowicka (ORCID: https://orcid.org/0000-0001-9707-8768)
- Tracy Burrows (ORCID: https://orcid.org/0000-0002-1431-7864)
- Eric Clarke (ORCID: https://orcid.org/0000-0003-0375-6797)
- A. Jansson
- Linnea E. Hedin
- Rachael Taylor (ORCID: https://orcid.org/0000-0002-3457-207X)
- Clare Collins
- Marie Löf (ORCID: https://orcid.org/0000-0002-2273-4430)
- Jordan Stanford (ORCID: https://orcid.org/0000-0003-3541-8960)
- T. Bucher
- Nienke de Vlieger (ORCID: https://orcid.org/0000-0002-0433-0571)
- Afsaneh Koochek (ORCID: https://orcid.org/0000-0002-0142-4724)
- Clair Sullivan
- V. Cross
- María Gómez‐Martín
- Roberta C. Asher
- Leonie H. Bogl
Institutions
- Uppsala University (SE)
- Queensland Health (AU)
- Bern University of Applied Sciences (CH)
- Karolinska University Hospital (SE)
- The University of Queensland (AU)
- Hunter Water (AU)
- Karolinska Institutet (SE)
- Hunter Medical Research Institute (AU)
- Metro South Health (AU)
- University of Newcastle Australia (AU)
Publication Details
- Journal
- Obesity Reviews
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/obr.70077
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 61.46
Funders
- Medical Research Council
- National Health and Medical Research Council